Medtronic has completed a US$90 million investment in Anteris Technologies, closed immediately following Anteris’ public offering of common stock.
Anteris has said that the funds raised will support execution of its global pivotal PARADIGM trial and advance global commercialisation of the DurAVR transcatheter heart valve (THV). DurAVR is a balloon-expandable, 3D single-piece transcatheter aortic valve implantation (TAVI) device, which is shaped to mimic the native human valve.
The PARADIGM trial is a prospective randomised controlled trial (RCT) which will evaluate the safety and effectiveness of DurAVR compared to commercially available TAVI systems. The US Food and Drug Administration (FDA) granted approval to initiate the investigational device exemption (IDE) trial in November 2025.
“This strategic investment, along with our underwritten offering of common stock, represent an important milestone for our company. It also provides strong validation of our program from the capital markets and a major strategic innovator,” said Wayne Paterson, Anteris vice chairman and chief executive. “The investment is one aspect of a collaboration that may expand into other strategic areas in the future. Anteris has developed a clinically important, evidence-supported product designed to improve the lives of patients with aortic stenosis as we advance toward regulatory approval.”
“The board is excited to welcome Medtronic to its stockholder community,” said John Seaberg, chairman of the Anteris board. “This investment aligns two organisations in their commitment to advancing valve science in a way that is disciplined and focused on long‑term patient benefit.”
“Medtronic is a pioneer in TAVI innovation and evidence,” said Jorie Soskin, vice president and general manager of the Structural Heart business in Medtronic’s cardiovascular portfolio. “Our investment in differentiated innovation like the DurAVR THV [transcatheter heart valve] technology—which has the potential to offer improved valve performance in a balloon-expandable platform—is core to our commitment to define and drive the future of TAVR, meeting the needs of more aortic stenosis patients and heart teams with a comprehensive portfolio.”
